MYOVIEW Drug Patent Profile
✉ Email this page to a colleague
When do Myoview patents expire, and what generic alternatives are available?
Myoview is a drug marketed by Medi-physics and is included in one NDA. There is one patent protecting this drug.
The generic ingredient in MYOVIEW is technetium tc-99m tetrofosmin kit. There are four drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the technetium tc-99m tetrofosmin kit profile page.
DrugPatentWatch® Generic Entry Outlook for Myoview
Myoview was eligible for patent challenges on February 9, 2000.
Indicators of Generic Entry
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for MYOVIEW?
- What are the global sales for MYOVIEW?
- What is Average Wholesale Price for MYOVIEW?
Summary for MYOVIEW
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 1 |
| Clinical Trials: | 2 |
| Drug Prices: | Drug price information for MYOVIEW |
| What excipients (inactive ingredients) are in MYOVIEW? | MYOVIEW excipients list |
| DailyMed Link: | MYOVIEW at DailyMed |
Recent Clinical Trials for MYOVIEW
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Astellas Pharma Inc | Phase 2 |
| GE Healthcare | Phase 4 |
US Patents and Regulatory Information for MYOVIEW
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Medi-physics | MYOVIEW | technetium tc-99m tetrofosmin kit | INJECTABLE;INJECTION | 020372-001 | Feb 9, 1996 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Medi-physics | MYOVIEW 30ML | technetium tc-99m tetrofosmin kit | INJECTABLE;INJECTION | 020372-002 | Jul 7, 2005 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for MYOVIEW
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Medi-physics | MYOVIEW | technetium tc-99m tetrofosmin kit | INJECTABLE;INJECTION | 020372-001 | Feb 9, 1996 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for MYOVIEW
See the table below for patents covering MYOVIEW around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Denmark | 163289 | ⤷ Sign Up | |
| China | 101861170 | Improved radiopharmaceutical composition | ⤷ Sign Up |
| Taiwan | 206231 | ⤷ Sign Up | |
| Spain | 2082771 | ⤷ Sign Up | |
| United Kingdom | 8808414 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for MYOVIEW
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1178838 | 300736 | Netherlands | ⤷ Sign Up | PRODUCT NAME: TILMANOCEPT, DESGEWENST GELABELD MET TECHNETIUM TC 99M; REGISTRATION NO/DATE: EU/1/14/955 20141119 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
